Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-956mj Total loading time: 0 Render date: 2025-03-02T20:37:44.992Z Has data issue: false hasContentIssue false

Chapter 22 - Myelodysplasia

from Section 3, Part E - Hypoplastic Anemias

Published online by Cambridge University Press:  18 April 2018

By
Ida Wong-Sefidan  and
Rafael Bejar
Edited by
Edward J. Benz, Jr. ,
Nancy Berliner  and
Fred J. Schiffman
Edward J. Benz, Jr.
Affiliation:
Dana Farber Cancer Institute
Nancy Berliner
Affiliation:
Brigham and Women's Hospital, Boston
Fred J. Schiffman
Affiliation:
Children's Hospital, Boston
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Anemia
Pathophysiology, Diagnosis, and Management
 , pp. 156 - 166
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Sekeres, MA, Schoonen, WM, Kantarjian, H, List, A, Fryzek, J, Paquette, R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. Journal of the National Cancer Institute. 2008; 100(21):1542–1551.CrossRefGoogle ScholarPubMed
Rollison, DE, Howlader, N, Smith, MT, Strom, SS, Merritt, WD, Ries, LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1):45–52.CrossRefGoogle ScholarPubMed
Goldberg, SL, Chen, E, Corral, M, Guo, A, Mody-Patel, N, Pecora, AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28(17):2847–2852.Google Scholar
Pedersen-Bjergaard, J, Daugaard, G, Hansen, SW, Philip, P, Larsen, SO, Rorth, M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991; 338(8763):359–363.Google Scholar
Liew, E, Owen, C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011; 96(10):1536–1542.CrossRefGoogle ScholarPubMed
Hoffman, R. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2009:xxvii, 2523.Google Scholar
Hsu, AP, Sampaio, EP, Khan, J, Calvo, KR, Lemieux, JE, Patel, SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011; 118(10):2653–2655.CrossRefGoogle ScholarPubMed
Bejar, R, Levine, R, Ebert, BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(5):504–515.Google Scholar
Walter, MJ, Shen, D, Ding, L, Shao, J, Koboldt, DC, Chen, K, et al. Clonal architecture of secondary acute myeloid leukemia. The New England Journal of Medicine. 2012; 366(12):1090–1098.CrossRefGoogle ScholarPubMed
Haase, D, Germing, U, Schanz, J, Pfeilstocker, M, Nosslinger, T, Hildebrandt, B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110(13):4385–4395.CrossRefGoogle ScholarPubMed
List, A, Dewald, G, Bennett, J, Giagounidis, A, Raza, A, Feldman, E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine. 2006; 355(14):1456–1465.CrossRefGoogle ScholarPubMed
Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012; 30(27):3376–3382.Google Scholar
Papaemmanuil, E, Gerstung, M, Malcovati, L, Tauro, S, Gundem, G, Van Loo, P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616–3627; quiz 99.Google Scholar
Haferlach, T, Nagata, Y, Grossmann, V, Okuno, Y, Bacher, U, Nagae, G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241–247.Google Scholar
Bejar, R, Stevenson, K, Abdel-Wahab, O, Galili, N, Nilsson, B, Garcia-Manero, G, et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine. 2011; 364(26):2496–2506.Google Scholar
Yoshida, K, Sanada, M, Shiraishi, Y, Nowak, D, Nagata, Y, Yamamoto, R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64–69.CrossRefGoogle ScholarPubMed
Christiansen, DH, Andersen, MK, Pedersen-Bjergaard, J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001; 19(5):1405–1413.Google Scholar
Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016; 128(16):2096–2067.CrossRefGoogle ScholarPubMed
Valent, P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012:485–491.Google ScholarPubMed
Arber, DA, Orazi, A, Hasserjian, R, Thiele, J, Borowitz, MJ, Le Beau, MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405.CrossRefGoogle Scholar
Bejar, R, Greenberg, PL. The impact of somatic and germline mutations in myelodysplastic syndromes and related disorders. Journal of the National Comprehensive Cancer Network. 2017; 15(1):131–135.Google Scholar
Network NCC. National Comprehensive Cancer Network Guidelines: Myelodysplatic Syndromes Version 2.2014 275 Commerce Drive, Suite 300, Fort Washington, PA 190342013 Version 2.2014: Available from: www.nccn.org.Google Scholar
Cargo, CA, Rowbotham, N, Evans, PA, Barrans, SL, Bowen, DT, Crouch, S, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015; 126(21):2362–2365.Google Scholar
Kwok, B, Hall, JM, Witte, JS, Xu, Y, Reddy, P, Lin, K, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015; 126(21):2355–2361.CrossRefGoogle ScholarPubMed
Greenberg, P, Cox, C, LeBeau, MM, Fenaux, P, Morel, P, Sanz, G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079–2088.Google Scholar
Garcia-Manero, G, Shan, J, Faderl, S, Cortes, J, Ravandi, F, Borthakur, G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008; 22(3):538–543.CrossRefGoogle ScholarPubMed
Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology. 2012; 30(27):3376–3382.Google Scholar
Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454–2465.Google Scholar
Greenberg, PL, Stone, RM, Al-Kali, A, Barta, SK, Bejar, R, Bennett, JM, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017; 15(1):60–87.CrossRefGoogle ScholarPubMed
Hellstrom-Lindberg, E, Gulbrandsen, N, Lindberg, G, Ahlgren, T, Dahl, IM, Dybedal, I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. 2003; 120(6):1037–1046.Google Scholar
Greenberg, PL, Sun, Z, Miller, KB, Bennett, JM, Tallman, MS, Dewald, G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009; 114(12):2393–2400.CrossRefGoogle ScholarPubMed
Passweg, JR, Giagounidis, AA, Simcock, M, Aul, C, Dobbelstein, C, Stadler, M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care–SAKK 33/99. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(3):303–309.Google Scholar
Malcovati, L, Porta, MG, Pascutto, C, Invernizzi, R, Boni, M, Travaglino, E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005; 23(30):7594–7603.CrossRefGoogle ScholarPubMed
Cutler, CS, Lee, SJ, Greenberg, P, Deeg, HJ, Perez, WS, Anasetti, C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2):579–585.Google Scholar
Koreth, J, Pidala, J, Perez, WS, Deeg, HJ, Garcia-Manero, G, Malcovati, L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013; 31(21):2662–2670.Google Scholar
Silverman, LR, Demakos, EP, Peterson, BL, Kornblith, AB, Holland, JC, Odchimar-Reissig, R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002; 20(10):2429–2440.CrossRefGoogle ScholarPubMed
Kadia, TM, Jabbour, E, Kantarjian, H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Seminars in Oncology. 2011; 38(5):682–692.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×